focus -WSS

focus

author：explore 2025-09-06 04:36:34 - browse：39

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： More regulation could be coming for drug ads

Wikipedia

WSS

Immune cells and nerve overgrowth may explain recurring UTI pain

For AI in health care standards, federal regulators join with industry group

Florida health officials providing scant details on measles cases

In venture capital firm's success, lessons for turning crisis into profit

An Ebola outbreak presents a new mystery involving children

Microsoft's Peter Lee: Generative AI could help doctors be more human

explore

focus

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Change Healthcare: What is it, why does its cyberattack matter?

Medicare details structure of new drug price negotiation program

$1 billion proposal to grow Boston, Massachusetts biotech

George Santos makes 1st court appearance after pleading not guilty to 13 counts

An Ebola outbreak presents a new mystery involving children

Moonlake's readout produced a cash windfall. Risks remain

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

How one medical school became remarkably diverse

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

hotspot

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Biden's 'march

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Stem cell biologist probes earliest stages of human development

First over

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

explore

knowledge

Wikipedia

knowledge